35 CambridgePark Drive
Cambridge, MA 02140
617 744 1340
Full-time employees: 117
|Dr. Nancy A. Simonian M.D.||Pres, CEO & Director||955.39k||N/A||1961|
|Dr. Richard A. Young Ph.D.||Scientific Founder, Member of Scientific Advisory Board & Director||108.37k||N/A||1954|
|Dr. Eric R. Olson Ph.D.||Chief Scientific Officer||667.6k||N/A||1958|
|Dr. David A. Roth M.D.||Chief Medical Officer||679.52k||N/A||1963|
|Dr. James E. Bradner M.D.||Founder||N/A||N/A||1972|
|Dr. Nathanael S. Gray Ph.D.||Scientific Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Jason Haas||Chief Financial Officer||N/A||N/A||1968|
|Ms. Karen Hunady M.S.||Director of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Gerald E. Quirk Esq., J.D.||Chief Legal Officer||N/A||N/A||1968|
|Ms. Lisa Roberts||VP of HR||N/A||N/A||N/A|
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Syros Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 June 2023 is 7. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 8; Compensation: 8.